Clinical Trial Update: EFFICACY AND TOLERABILITY OF BECLOMETHASONE DIPROPIONATE 100 µg + FORMOTEROL 6 µg pMDI VIA HFA-134a vs. FLUTICASONE 125 µg + SALMETEROL 25 µg pMDI [Phase 3]

View source ↗

Summary

Phase 3 trial comparing budesonide/formoterol pMDI vs fluticasone/salmeterol pMDI for bronchial asthma, completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchial Asthma

Drugs mentioned

• Becolomethasone Dipropionate 100 µg + Formoterol 6 µg pMDI (HFA-134a) (budesonide/formoterol)
• Fluticasone 125 µg + Salmeterol 25 µg pMDI (fluticasone/salmeterol)

Snippet

Sponsor: Chiesi Farmaceutici S.p.A. | Conditions: Bronchial Asthma | Phase 3 | Status: COMPLETED